Table 1.
Patient Characteristics (n=1068)
| Variable | LGE (N=448) | No LGE (N=620) | P Value |
|---|---|---|---|
| Demographics | |||
| Age, median (Q1 to Q3), y | 59 (51 to 69) | 53 (39 to 63) | <0.001 |
| Female, n (%) | 123 (27) | 313 (50) | <0.001 |
| White race, n (%) | 397 (89) | 545 (88) | 0.72 |
| Black race, n (%) | 44 (10) | 52 (8) | 0.42 |
| General indication for CMR exam | |||
| Known or suspected cardiomyopathy, n (%) | 211 (47) | 274 (44) | 0.35 |
| Possible coronary disease/viability/vasodilator stress testing, n (%) | 233 (52) | 215 (35) | <0.001 |
| Evaluation for arrhythmia substrate*, n (%) | 85 (19) | 207 (33) | <0.001 |
| Possible mass or thrombus, n (%) | 25 (6) | 23 (4) | 0.15 |
| Comorbidity | |||
| Diabetes, n (%) | 117 (26) | 93 (15) | <0.001 |
| Hypertension, n (%) | 268 (60) | 260 (42) | <0.001 |
| Dyslipidemia, n (%) | 206 (46) | 196 (32) | <0.001 |
| Current cigarette smoking, n (%) | 79 (18) | 81 (13) | 0.04 |
| Atrial fibrillation or flutter, n (%) | 38 (8) | 57 (9) | 0.69 |
| Hospitalized/Inpatient status, n (%) | 188 (42) | 165 (27) | <0.001 |
| Prior coronary revascularization, n (%) | 149 (33) | 35 (6) | <0.001 |
| Body mass index, median (Q1 to Q3), kg/m2 | 28 (25 to 33) | 28 (24 to 34) | 0.44 |
| Baseline heart failure, n (%) | 123 (27) | 91 (15) | <0.001 |
| Heart failure stage, n (%) | |||
| 0 | 25 (6) | 169 (27) | <0.001 |
| A | 60 (13) | 223 (36) | |
| B | 248 (55) | 164 (26) | |
| C or D | 115 (26) | 64 (10) | |
| Medications | |||
| ACE inhibitor, angiotensin receptor blocker, or mineralocorticoid antagonist | 233 (52) | 200 (32) | <0.001 |
| Beta‐blockers | 299 (67) | 240 (39) | <0.001 |
| Aspirin or other antiplatelet | 277 (62) | 248 (40) | <0.001 |
| Statin | 227 (51) | 183 (30) | <0.001 |
| Loop diuretic | 127 (28) | 97 (16) | <0.001 |
| Laboratory and CMR characteristics | |||
| Creatinine, median (Q1 to Q3), mg/dL | 0.9 (0.9 to 1.2) | 0.9 (0.8 to 1.0) | <0.001 |
| Glomerular filtration rate, median (Q1 to Q3), mL/min per 1.73 m2 | 81 (64 to 93) | 90 (73 to 92) | 0.001 |
| Ejection fraction, median (Q1 to Q3), % | 49 (34 to 61) | 60 (54 to 66) | <0.001 |
| Left ventricular mass index, median (Q1 to Q3), g/m2 | 69 (57 to 88) | 53 (44 to 64) | <0.001 |
| End diastolic volume index, median (Q1 to Q3), mL/m2 | 91 (72 to 112) | 78 (66 to 91) | <0.001 |
| End systolic volume index, median (Q1 to Q3), mL/m2 | 44 (28 to 72) | 30 (23 to 40) | <0.001 |
| Moderate or severe mitral regurgitation by cine CMR, n (%) | 22 (5) | 17 (3) | 0.06 |
| Myocardial infarction, n (%) | 203 (45) | — | — |
| Acute myocardial infarction, n (%) | 63 (14) | — | — |
| Nonischemic or atypical scar evident on LGE images, n (%) | 273 (61) | — | — |
| Amyloid suspected by LGE, n (%) | 15 (3) | — | — |
ACE indicates angiotensin‐converting enzyme; CMR, cardiovascular magnetic resonance; LGE, late gadolinium enhancement.
*
Arrhythmia substrate refers to evaluating patients with known or suspected ventricular arrhythmia for structural heart disease.